The global urothelial cancer treatment market is estimated to grow at a CAGR of around 12% during the forecast period. Urothelial cancer is also called transitional cell cancer. Urothelial cancer is a type of bladder cancer, 90% of the bladder cancer cases are accounted for it and globally urothelial cancer is the 9th most common malignancy. According to the National Cancer Institute (NCI), in 2019, estimated new cases of Bladder cancer were 80,470 and 17,670 were death cases. According to the American Cancer Society (ACS) in 2020, there will be around 81,400 new cases for bladder cancer. Among them, 62,100 are men and 19,300 are women.

Availability of drugs, innovations & pipelines, rising cases of urothelial cancer due to growing geriatric population, and growing public awareness is propelling the global urothelial cancer treatment market growth. Urothelial cancer mostly affects older people, 90% of the urothelial cancer patients are older than 55 years and the average age of people are diagnosed with urothelial cancer is 73 years. According to the International Agency for Research on Cancer (IARC), among all bladder cancer cases, 59% are from the developed countries. Belgium reported the highest number of bladder cancer cases. The rise of this disease is gearing the growth of the urothelial cancer drugs market.

Moreover, government initiatives and many social awareness campaigns held my NOGs is one of the drivers of this market. For instance, Bladder Cancer Advocacy Network (BCAN) organize “ Walk to end bladder cancer”  to create social awareness about bladder cancer as well as urothelial cancer among the public. The US health advocate and health authorities conduct prostate health awareness campaign the “National Prostate Health Month” every year in September, to educate the people about the risk and treatment, that are associates with benign prostatic hyperplasia. However, less reimbursement scenario and high cost of therapy are restraining the market growth.

Segmentation

The global urothelial cancer treatment market is segmented based on the therapy type that includes chemotherapy, immunotherapy, and others. The chemotherapy segment held a significant share in the therapy segment in 2018. Usually, cancer cells divide and grow very fastly, chemotherapy destroys the cancer cells and stops it from growing. Chemotherapy is of two types, which are Intravesical chemotherapy and Systemic chemotherapy. Intravesical chemotherapy is also called local chemotherapy, it is usually given by the urologists. In this treatment, only those superficial tumor cells are destroyed which come in contact with chemotherapy solution. Tumor cells in the bladder wall or tumor cells that have spread to other parts can’t be treated by Intravesical or local chemotherapy.

Some of the major drugs used in Intravesical chemotherapy include Mitomycin-C (available as a generic drug), gemcitabine (Gemzar), and thiotepa (Tepadina), and others. Systemic chemotherapy is used to treat urothelial cancer. In systemic chemotherapy combination of drugs is used for treatment. Researchers found that it is the best method for the treatment of urothelial cancer. Some of the major drug combinations used in systemic chemotherapy are Cisplatin & gemcitabine, Carboplatin & gemcitabine, methotrexate & vinblastine & doxorubicin & cisplatin, and others.

Global Urothelial Cancer Treatment Market Share by Therapy Type, 2018 (%)

Regional Outlook

North America is expected to have a significant market share in the global urothelial cancer treatment market due to the high prevalence rate of urothelial cancer. Key factors that are driving the market include the availability of proper healthcare infrastructures and the presence of the major players offering innovative urothelial cancer drugs in the market. Moreover, the Asia-Pacific region is the fastest-growing urothelial cancer drug market, owing to the large numbers of the patient, growing economy, the presence of an established drug market, and increasing health awareness.

Global Urothelial Cancer Treatment Market Growth, by Region 2019-2025

Competitive Landscape

The major players providing urothelial cancer treatment include Merck & Co. Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Pfizer Inc., Novartis AG, GlaxoSmithKline PLC, Sanofi SA, Eisai Co. Ltd. Range of urothelial cancer drugs manufactured by these key players including KEYTRUDA (pembrolizumab), Tecentriq (atezolizumab), Opdivo (nivolumab), Durvalumab, Lenvima, and others. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance,in May 2018, Merck & Co. Inc got FDA approval for KEYTRUDA (pembrolizumab), anurothelial cancer drug, can be used for certain patients with locally advanced or metastatic urothelial carcinoma.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global urothelial cancer treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies